Cargando…

Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis

Background: Glatiramer acetate (GA) is a well-established treatment option for patients with clinically isolated syndrome and relapsing–remitting multiple sclerosis (MS) with few side effects. The double transgenic mouse model spontaneous opticospinal encephalomyelitis (OSE), based on recombinant my...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koc, Ümmügülsüm, Haupeltshofer, Steffen, Klöster, Katharina, Demir, Seray, Gold, Ralf, Faissner, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954767/ https://www.ncbi.nlm.nih.gov/pubmed/36831209 http://dx.doi.org/10.3390/cells12040542

Ejemplares similares

Progressive Retinal and Optic Nerve Damage in a Mouse Model of Spontaneous Opticospinal Encephalomyelitis
por: Petrikowski, Laura, et al.
Publicado: (2022)

Clozapine Regulates Microglia and Is Effective in Chronic Experimental Autoimmune Encephalomyelitis
por: Ceylan, Ulaş, et al.
Publicado: (2021)

Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)

Immunomodulatory therapy with glatiramer acetate reduces endoplasmic reticulum stress and mitochondrial dysfunction in experimental autoimmune encephalomyelitis
por: Makar, Tapas K., et al.
Publicado: (2023)

Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
por: Komlosh, Arthur, et al.
Publicado: (2019)

Synthetic Cationic Autoantigen Mimics Glatiramer Acetate Persistence at the Site of Injection and Is Efficacious Against Experimental Autoimmune Encephalomyelitis
por: Song, Jimmy Y., et al.
Publicado: (2021)

Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis
por: Ortíz, Genaro Gabriel, et al.
Publicado: (2022)

Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone(®)
por: Lipsky, Peter, et al.
Publicado: (2021)

Treatment of Chronic Experimental Autoimmune Encephalomyelitis with Epigallocatechin-3-Gallate and Glatiramer Acetate Alters Expression of Heme-Oxygenase-1
por: Janssen, Antonia, et al.
Publicado: (2015)

Enhanced disease reduction using clozapine, an atypical antipsychotic agent, and glatiramer acetate combination therapy in experimental autoimmune encephalomyelitis
por: Green, Laura K, et al.
Publicado: (2017)

Safety of potential breast milk exposure to IFN-β or glatiramer acetate: One-year infant outcomes
por: Ciplea, Andrea Ines, et al.
Publicado: (2020)

The role of glatiramer acetate in the early treatment of multiple sclerosis
por: Brandes, David W
Publicado: (2010)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Glatiramer Acetate-associated Refractory Immune Thrombocytopenic Purpura
por: Sagy, Iftach, et al.
Publicado: (2016)

Bullous pemphigoid as an injection site reaction of glatiramer acetate
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2019)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
por: Kasindi, Arielle, et al.
Publicado: (2022)

An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate
por: Erzina, Dina, et al.
Publicado: (2021)

Glatiramer acetate attenuates the activation of CD4(+) T cells by modulating STAT1 and −3 signaling in glia
por: Ahn, Ye-Hyeon, et al.
Publicado: (2017)

Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience
por: de Oliveira, Tatiana de Melo Gomes, et al.
Publicado: (2008)

Glatiramer acetate desensitisation in multiple sclerosis patients - the case report
por: Novotna, Bronislava, et al.
Publicado: (2014)

Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
por: Izquierdo, Guillermo, et al.
Publicado: (2015)

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial
por: Arnold, Douglas L., et al.
Publicado: (2013)

Metabolic response to glatiramer acetate therapy in multiple sclerosis patients
por: De Riccardis, Lidia, et al.
Publicado: (2016)

Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
por: D’Alessandro, Josephine, et al.
Publicado: (2017)

Process signatures in glatiramer acetate synthesis: structural and functional relationships
por: Campos-García, Víctor R., et al.
Publicado: (2017)

Embolia Cutis Medicamentosa after Subcutaneous Injection with Glatiramer Acetate
por: Vlahova, Lyubomira, et al.
Publicado: (2021)

Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis
por: Waschbisch, Anne, et al.
Publicado: (2011)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
por: Fernández, Oscar
Publicado: (2012)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2009)

Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic
por: Towfic, Fadi, et al.
Publicado: (2014)

Glatiramer acetate treatment negatively regulates type I interferon signaling
Publicado: (2015)

Restoration of Axon Conduction and Motor Deficits by Therapeutic Treatment with Glatiramer Acetate
por: Moore, Spencer, et al.
Publicado: (2014)

Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study
por: Davis, Mat D., et al.
Publicado: (2017)

Glatiramer acetate treatment negatively regulates type I interferon signaling
por: Molnarfi, Nicolas, et al.
Publicado: (2015)

Glatiramer acetate does not protect from acute ischemic stroke in mice
por: Kraft, Peter, et al.
Publicado: (2014)

Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis
por: Kuerten, Stefanie, et al.
Publicado: (2018)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis
por: Melnikov, Mikhail, et al.
Publicado: (2020)

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
por: Mirabella, Massimiliano, et al.
Publicado: (2022)

Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment
por: Caporro, Matteo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6so6tnkjioi3bt0s919cf0d9db